Given that the genetic instrument used for ACE levels was associated with lower systolic blood pressure, people with these variants may be less likely to develop hypertension and subsequently less likely to be prescribed and treated with pharmacological ACE inhibitors. This evidence concerns the gene ACE and hypertensive disorder.